XFOR stock forecast
Our latest prediction for X4 Pharmaceuticals Inc's stock price was made on the June 16, 2022 when the stock price was at 1.07$.
In the short term (2weeks), XFOR's stock price should outperform the market by 3.55%. During that period the price should oscillate between -12.12% and +20.00%.
In the medium term (3months), XFOR's stock price should outperform the market by 30.80%. During that period the price should oscillate between -46.52% and +69.89%.Get email alerts
Create a solid portfolio with XFOR
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company's lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials - in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -3.41$ per share.
The book value per share is 8.01$
Three months stock forecastJune 16, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|